Bedminster-based Amarin Corporation plc, a biopharmaceutical company focused on cardiovascular health therapies, announced Monday that it has promoted Aaron Berg to senior vice president, chief commercial officer.
Berg previously served as the company’s senior vice president, marketing and sales.
Prior to Amarin, he was CEO and president of Essentialis Inc. Before that, he was vice president of marketing and sales at Kos Parmaceuticals. He began his career as a sales representative with Bristol-Myers Squibb, followed by commercial positions with Schering-Plough and GlaxoSmithKline.
Berg will be responsible for the commercial growth for one of Amarin’s drug therapies, Vascepa.
“Aaron has made invaluable contributions to Amarin over multiple years,” said John F. Thero, CEO and president of Amarin. “He has wide-ranging experience and comprehensive knowledge of our industry combined with an entrepreneurial spirit and a collaborative approach which makes him broadly respected and well-positioned to help lead Amarin in fulfilling our commercial opportunities. We are excited to work with Aaron in this important leadership position.”
